Positive Expression Rate Of HER-2 Research Articles

Expressions of growth factor receptor binding protein 7 and human epidermal growth factor receptor 2 in endometrial carcinoma and their significances

Objective To investigate the expressions of growth factor receptor binding protein 7(GRB7) and human epidermal growth factor receptor 2 (HER2) in endometrial carcinoma and their clinical significances. Methods Immunohistochemistry was used to detect the expressions of GRB7 and HER2 in 52 endometrial carcinoma tissues, 38 endometrial atypical hyperplasia tissues and 30 normal endometrial tissues collected from patients in the Sixth People's Hospital of Shanghai Jiao Tong University from May 2015 to September 2017. The relationship between the expressions of GRB7 and HER2 and clinicopathological features of endometrial carcinoma patients was analyzed. Results The positive expression rates of GRB7 in endometrial carcinoma, endometrial atypical hyperplasia and normal endometrial tissues were 71.2% (37/52), 39.5% (15/38), and 13.3% (2/30), respectively, and the difference was statistically significant (χ2 = 35.14, P < 0.05). The positive expression rates of HER2 in endometrial carcinoma, endometrial atypical hyperplasia and normal endometrial tissues were 67.3% (35/52), 34.2% (13/38), and 10.0% (3/30), respectively, and the difference was statistically significant (χ2 = 29.360, P < 0.05). The positive expression rates of GRB7 in endometrial carcinoma patients with different clinical stages, histological grades and pathological types were statistically significant (all P < 0.05). The positive expression rates of HER2 in endometrial carcinoma patients with different clinical stages, histological grades, lymph nodes metastasis and myometrial invasion were statistically significant (all P < 0.05). The expression of GRB7 in endometrial carcinoma was positively correlated with the expression of HER2(r = 0.375, P < 0.05). Conclusion The high expressions of GRB7 and HER2 in endometrial carcinoma are closely related to the malignant degree of endometrial carcinoma. Key words: Endometrial neoplasms; Growth factor receptor binding protein 7; Human epidermal growth factor receptor 2; Neoplasm staging

P1.02-016 HER4 Expression Was Related to the Sensitivity of EGFR-TKI in Non-Small Cell Lung Cancer

EGFR-TKIs show significant therapeutic effects against non-small cell lung cancer (NSCLC) with EGFR-activating mutations, however 20-30% of them have no response to EGFR-TKIs. HER-family receptors play a critical role in tumor progression, differentiation and survival in lung cancer. Recent studies suggest that the overexpression of HER-family receptors have a potential risk of EGFR-TKIs resistance. The aims of this study were to investigate the association between EGFR-mutation and the expression of HER-family receptor in regard to clinical outcomes. We invested EGFR mutation by direct PCR analysis and HER2-4 expression by immunohistochemistry (IHC) of 231 consecutive non-small cell lung cancers, who had undertaken an operation from January 2007 to July 2012. The intensity of HER2-4 was graded (score: 0-3) from negative (score: 0-1) to positive (score: 2-3). The observed protein expression levels were analyzed for correlation to EGFR mutation status, clinicopathological parameters and the responses of EGFR-TKI treatment. EGFR mutation was observed in 40% of lung cancer, 61% of p. [Leu858Arg] and 31% of exon 19 deletion. Positive expression rates of HER2, HER3 and HER4 were 22.9%, 1.2%, 38.5%, respectively. HER4 positive rare of EGFR positive group was significantly higher than that of EGFR negative group (52% vs 30%, P<0.01), however there was no difference in HER2 expression. In histological type, positive rates of HER2 and HER4 in adenocarcinoma were higher than that in squamous cell carcinoma (HER2: 26% vs 13%, P=0.07, HER4: 49% vs 13%, P<0.01). HER4 positive rate of HER2 positive group was significantly lower that of HER2 negative group (43% vs 26%, P=0.03). The response rate of EGFR-TKIs in HER2 positive group was low, but high in HER4 positive group. Our data showed that HER4 expression was independent form EGFR mutation and HER2 expression, but related to the sensitivity against EGFR-TKIs. HER4 positive patients may be candidate for pan-HER inhibitor augments.

Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry.

The aim of this study was to compare quantitative polymerase chain reaction (qPCR) with immunohistochemistry (IHC) for the detection of Her-2 in gastric cancer, and to investigate the correlation between the expression levels of human epidermal growth factor receptor 2 (Her-2) and clinical features. Clinical data from 426 cases of gastric cancer were collected. Her-2 expression levels in cancerous tissue were detected using IHC, and the Her-2/neu gene expression levels were determined by qPCR. The correlation between the expression level of Her-2 and clinical features was investigated. The positive expression rate of Her-2 in cancerous tissue detected using qPCR and IHC was 11.17% (46/412) and 13.38% (57/426), respectively. The positive expression of the Her-2 protein/gene was significantly correlated with the depth of invasion and lymphatic metastasis, as well as the TNM stage (P<0.05). No significant correlation was identified between positive expression of the Her-2 protein/gene and tumor location, age, gender, differentiation degree and Lauren classification (P>0.05). The diagnostic consistency was good between the two methods (κ=0.828). The results indicate that the expression of Her-2/neu is closely associated with the development of gastric cancer. qPCR is a convenient, objective and efficient method, which may be used as an alternative to IHC or fluorescence in situ hybridization for the detection of Her-2/neu gene.